Filing Flows

Filing Flows › Companies › International Stem Cell › Cash flow

International Stem Cell cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$160K in Q2 2026 · $333K over twelve months

Operating cash flow$167K
Capital spending−$7K
Free cash flow+$160K
Cash conversion cycle131 days

Analysis

In Q2 2026, International Stem Cell generated $167K of operating cash flow and spent $7K on capital projects, leaving free cash flow of $160K. That is $492K more than in Q2 2025 (−$332K).

Over the twelve months to Jun 30, 2026, operating cash flow was $369K; the largest uses were other financing ($150K), capital spending ($36K), other investing ($14K); the cash balance rose by $169K.

Operating cash flow was $167K against net income of −$71K. The largest differences: receivables −$168K, prepaid and other assets +$129K, accrued liabilities +$128K.

Its cash conversion cycle was 131 days (receivables 30 + inventory 129 − payables 28).

Free cash flow

International Stem Cell: free cash flow by quarterInternational Stem Cell: free cash flow by quarter$220KQ3 2024−$75KQ4 2024$222KQ1 2025−$332KQ2 2025$46KQ3 2025$29KQ4 2025$98KQ1 2026$160KQ2 2026
Operating cash flow less capital spending.
International Stem Cell: operating cash flow against capital spendingInternational Stem Cell: operating cash flow against capital spendingOperating cash flowCapital spending$257K$37KQ3 2024−$74K$1KQ4 2024$227K$5KQ1 2025−$300K$32KQ2 2025$49K$3KQ3 2025$32K$3KQ4 2025$121K$23KQ1 2026$167K$7KQ2 2026
Latest (Q2 2026): Operating cash flow $167K, Capital spending $7K.

Capital allocation, year by year

International Stem Cell: where the cash came from (up) and went (down), by fiscal yearInternational Stem Cell: where the cash came from (up) and went (down), by fiscal yearOperating cash flowCapital spendingFY2021: Operating cash flow −$1.3MFY2021: Capital spending −$23KFY2021FY2022: Operating cash flow $332KFY2022: Capital spending −$1K$332KFY2022FY2023: Operating cash flow $929KFY2023: Capital spending −$80K$929KFY2023FY2024: Operating cash flow $13KFY2024: Capital spending −$166K$13KFY2024FY2025: Operating cash flow $8KFY2025: Capital spending −$43K$8KFY2025
Over these 5 years operating cash flow totalled −$15K; the largest uses were operating cash flow ($1.3M) and capital spending ($313K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.1M
Debtnone
Net cash$1.1M

International Stem Cell funds itself: free cash flow was $333K over the last twelve months, with $1.1M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

International Stem Cell: sources (+) and uses (−) of cash, Q2 2026International Stem Cell: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$167KCash drawn (+) / kept (−)−$156KCapital spending−$7KOther investing−$4K
International Stem Cell: sources (+) and uses (−) of cash, TTM to Q2 2026International Stem Cell: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$369KCash drawn (+) / kept (−)−$169KOther financing−$150KCapital spending−$36KOther investing−$14K

From profit to cash

International Stem Cell: net income to operating cash flow, Q2 2026International Stem Cell: net income to operating cash flow, Q2 2026Net income−$71KDepreciation & amortization$28KStock-based pay$59KImpairments$111KGains on disposals−$120KReceivables−$168KInventory$43KPayables−$127KAccrued liabilities$128KPrepaid and other assets$129KOperating cash flow$167K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263012928131
Q1 20262915529156
Q4 20253713419152
Q3 20254113829150
Q2 20253613842132
Q1 20254010929120
Q4 20243311824127
Q3 20243113233131

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q2 2026$167K−$7K−$156K$160K
Q1 2026$121K−$23K$60K$98K
Q4 2025$32K−$3K−$27K$29K
Q3 2025$49K−$3K−$46K$46K
Q2 2025−$300K−$32K$532K−$332K
Q1 2025$227K−$5K−$222K$222K
Q4 2024−$74K−$1K$77K−$75K
Q3 2024$257K−$37K−$17K$220K

International Stem Cell: income statement and cash flow

International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%. The chart follows the revenue to costs, profit and cash.

International Stem Cell: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.